Eaze has completed $13 million in Series B financing, raising its total to $25 million, the company announced in a press release. Eaze provides “on-demand” medical cannabis delivery in nearly 100 California cities and its EazeMD platform helps connect patients with board-certified doctors. Additionally, the company offers a Brand Insights Program, which allows product manufacturers to track industry trends based on data from Eaze customer interactions.
Keith McCarty, Eaze CEO, said the funding puts the San Francisco-based company in a position “to accelerate as the market hits an inflection point.”
“This is a critical time for the marijuana industry. Adult use is on the precipice of becoming legal in California, the largest marijuana market in the United States,” he said in the release. “Eaze is setting a new standard for accessibility, safety, and professionalism, which makes it best positioned to educate and service the future market.”
Davis Chao, a partner at venture capitalist firm DCM Ventures — who has participated in two rounds of Eaze funding and provided seed funding — said that McCarty’s “tech background and commitment to professionalism and compliance” made investing with the firm a “no brainer,” noting that the group will continue investing in the company “as it continues to exceed” expectations.
Get daily cannabis business news updates. Subscribe